stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Shares outstanding
IDEAYA Biosciences, Inc.'s shares outstanding at the end of fiscal 2025 was $88.5M, up 8.33% from $81.7M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $102.9M. Over the past ten years it has ranged from $695.0K (fiscal 2017) to $88.5M (fiscal 2025) — the current reading is the highest in ten years. IDEAYA Biosciences, Inc. ranks 142nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $88.5M | 8.33% |
| FY2024 | $81.7M | 42.00% |
| FY2023 | $57.5M | 38.79% |
| FY2022 | $41.4M | 17.57% |
| FY2021 | $35.3M | 42.59% |
| FY2020 | $24.7M | 97.82% |
| FY2019 | $12.5M | 1,207.22% |
| FY2018 | $956.0K | 37.55% |
| FY2017 | $695.0K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $102.9M | 11.82% |
| Jun 2026 | $92.1M | 3.79% |
| Mar 2026 | $88.7M | 0.24% |
| Dec 2025 | $88.5M | (1.34%) |
| 29 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. compare | $192.1M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| BEAM Beam Therapeutics Inc. compare | $104.7M |
| IDYA IDEAYA Biosciences, Inc. | $102.9M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement